Asia Pacific Insulin Market Is Projected To Grow Due To Increasing Market Penetration Rates Of Modern Insulin Product Till 2020: Grand View Research, Inc.
The Asia Pacific insulin market is expected to reach
USD 15.04 billion by 2020, according to a new study by Grand View Research,
Inc. Growing regional prevalence of diabetes, increasing market penetration
rates of modern insulin products in emerging markets such as India and China is
expected to drive market growth during the forecast period. Furthermore, patent
expiration of key products such as Lantus is expected to trigger the
manufacturing of biosimilars from local manufacturers such as Biocon.
Long acting analog dominated the
overall market in terms of revenue share in 2013, with revenue estimated at USD
2,051.9 million. High prices coupled with relatively higher efficacies
exhibited by these products account for its large share. Rapid acting analogs
followed the long acting segment in 2013 accounting for a revenue share of over
25.0% on account of their high market penetration rates in developed markets
such as Australia and Japan.
Browse full research report on Asia Pacific Insulin
Market: http://www.grandviewresearch.com/industry-analysis/asia-pacific-insulin-market
Further key findings from the study suggest:
- The analogs source segment accounted for the largest
revenue share in 2013 was valued at USD 3,441.7 million. Growing demand
for analogs in emerging markets with high unmet medical needs such as
China and India is one of the major factors attributing to its large
share.
- Japan, on behalf of its sophisticated healthcare
infrastructure, high patient awareness and disposable income levels
dominated the market in 2013 with a revenue share of over 38.0%.
- China on the other hand is expected to register the
highest CAGR of 21.1% during the forecast period owing to the growing
prevalence of type I and type diabetes and the expected decline in insulin
prices as a result of continued initiatives to improve healthcare access.
- The Asia Pacific insulin market is oligopolistic in
nature and is dominated by three key players including Novo Nordisk, Eli
Lilly and Sanofi Aventis.
Browse more reports of this category by Grand View
Research: http://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the Asia Pacific Insulin
market on the basis of product, application, source and region:
Insulin Product Outlook
- Rapid
acting
- Long
acting
- Premixed
- Premixed
analog
- Short
acting
- Intermediate
acting
Insulin Application Outlook
- Type I
and Other Diabetes
- Type
II Diabetes
Insulin Source Outlook
- Human
Recombinant
- Analogs
Insulin Regional Outlook
- India
- China
- Australia
- New
Zealand
- South
Korea
- Taiwan
- Philippines
- Vietnam
- Indonesia
- Japan
- Malaysia
- Thailand
- Rest
of Asia Pacific
Access Press Release
By Grand View Research: http://www.grandviewresearch.com/press-release/asia-pacific-insulin
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
Comments
Post a Comment